Jiangxi Synergy Pharmaceutical Co., Ltd.

Jiangxi Synergy Pharmaceutical Co., Ltd. has recently experienced a change in its evaluation, reflecting a shift in its valuation metrics. Key financial indicators include a P/E ratio of 36 and a Price to Book Value of 1.44, amidst challenges such as declining operating profit margins and negative results over the past eight quarters.

Jiangxi Synergy Pharmaceutical Co., Ltd. has recently experienced a change in its evaluation, reflecting shifts in its technical score. The company remains net-debt-free but has encountered challenges in long-term growth, with declining operating profit despite a modest increase in net sales. Its recent performance has been below market averages.

Jiangxi Synergy Pharmaceutical Co., Ltd. saw its stock price decline significantly, contrasting with the broader market's performance. The company has faced ongoing challenges, including a high debt-to-equity ratio and negative results for eight consecutive quarters, while offering a modest dividend yield.

Jiangxi Synergy Pharmaceutical Co., Ltd. has experienced a recent evaluation adjustment, reflecting a change in its valuation metrics. Key financial indicators reveal a mixed performance, with challenges in long-term growth and ongoing financial pressures, including declining operating profit and negative results over the last eight quarters.